This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, Bruck W, Lucchinetti C, Schmidbauer M, Jellinger K, Lassmann H (2003) Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 62:25–33
Avramut M, Achim CL (2003) Immunophilins in nervous system degeneration and regeneration. Curr Top Med Chem 3:1376–1382
Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, Friese M, Schroder R, Deckert M, Schmidt S, Ravid R, Rajewsky K (2000) Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active MS lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192:393–404
Besser M, Wank R (1999) Clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 162:6303–6306
Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125:1297–1308
Butzkueven H, Zhang J-G, Soilu-Hänninen M, Hochrein H, Chionh F, Shipham KA, Emery B, Turnley AM, Petratos S, Ernst M, Bartlett PF, Kilpatrick TJ (2002) LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med 8:613–619
Cohen IR (1992) The cognitive paradigm and the immunological homunculus. Immunol Today 13:490–494
De Keyser J, Sulter G, Luiten PG (1999) Clinical trials with neuroprotective drugs in acute ischemic stroke: arewe doing the right thing? TrendsNeurosci 22:535–540
Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393–399
Flügel A, Willem M, Berkowicz T, Wekerle H (1999) Gene transfer into CD4+ T lymphocytes: Green fluorescent protein engineered, encephalitogenic T cells used to illuminate immune responses in the brain. NatMed 5:843–847
Giess R, Maurer M, Linker R, Gold R, Warmuth-Metz M, Toyka KV, Sendtner M, Rieckmann P (2002) Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol 59:407–409
Guo X, Dillman JF, III, Dawson VL, Dawson TM (2001) Neuroimmunophilins: novel neuroprotective and neuroregenerative targets. Ann Neurol 50:6–16
Hemmer B, Archelos JJ, Hartung H-P (2002) Newconcepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3:291–301
Hohlfeld R (1997) Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120:865–916
Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H (2000) The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis. J Neuroimmunol 107:161–166
Jacobsen M, Cepok S, Quak E, Happel M, Gaber R, Ziegler A, Schock S, Oertel WH, Sommer N, Hemmer B (2002) Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 125:538–550
Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH (2002) The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 8:532–533
Kerschensteiner M, Gallmeier E, Behrens L, Klinkert WEF, Kolbeck R, Hoppe E, Stadelmann C, Lassmann H, Wekerle H, Hohlfeld R (1999) Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: A neuroprotective role of inflammation? J Exp Med 189:865–870
Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R (2003) Neurotrophic cross-talk between the nervous and immune systems: Implications for neurological diseases. Ann Neurol 53:292–304
Kornek B, Lassmann H (1999) Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 9:651–656
Kramer R, Zhang Y, Gehrmann J, Gold R, Thoenen H, Wekerle H (1995) Gene transfer through the blood-nerve barrier: Nerve growth factor engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nat Med 1:1162–1166
Lassmann H (2003) Axonal injury in multiple sclerosis. J Neurol Neurosurg Psych 74:695–697
Lewin GR, Barde Y-A (1996) Physiology of the neurotrophins. Annu Rev Neurosci 19:289–317
Linker RA, Mäurer M, Gaupp S, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka KV, Sendtner M, Gold R (2002) CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation. Nat Med 8:620–624
Meinl E, Hoch RM, Dornmair K, De Waal Malefijt R, Bontrop RE, Jonker M, Lassmann H, Hohlfeld R, Wekerle H, ’t Hart BA (1997) Encephalitogenic potential ofmyelin basic protein-specificTcells isolated from normal rhesus macaques. AmJ Pathol 150:445–453
Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M(1999) Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 5:49–55
Neumann H, Medana IM, Bauer J, Lassmann H (2002) Cytotoxic Tlymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 25:313–319
Noseworthy JH, Gold R, Hartung H-P (1999) Treatment of multiple sclerosis: Recent trial and future perspectives. Curr Opin Neurol 12:279–293
Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID (2002) Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 51:215–223
Schwartz M, Moalem G, Leibowitz-Amit R, Cohen IR (1999) Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci 22:295–299
Skulina C, Schmidt S, Dornmair K, Babbe H, Roers A, Rajewsky K, Wekerle H, Hohlfeld R, Goebels N (2004) Multiple sclerosis: Brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci 101:2428–2433
Smith KJ, Lassmann H (2002) The role of nitric oxide in multiple sclerosis. Lancet Neurology 1:232–241
Torcia M, Bracci-Laudiero L, Lucibello M, Nencioni L, Labardi D, Rubatelli A, Cozzolino F, Aloe L, Garaci E (1996) Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell 85:345–356
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mørk S, Bø L (1998) Axonal transection in the lesion of multiple sclerosis. N Engl J Med 338:278–285
Ziemssen T, Kumpfel T, Klinkert WEF, Neuhaus O, Hohlfeld R (2002) Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain 125:2381–2391
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Hohlfeld, R., Kerschensteiner, M., Stadelmann, C., Lassmann, H., Wekerle, H. (2005). The Neuroprotective Effect of Inflammation: Implications for the Therapy of Multiple Sclerosis. In: Perez, H.D., Mitrovic, B., Baron Van Evercooren, A. (eds) Opportunities and Challenges of the Therapies Targeting CNS Regeneration. Ernst Schering Research Foundation Workshop, vol 53. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-27626-2_3
Download citation
DOI: https://doi.org/10.1007/3-540-27626-2_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-24082-2
Online ISBN: 978-3-540-27626-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)